Fig. 4

The change in eGFR overtime in initiators of GLP-1 RA versus basal insulin. At each time point (every 6 months for the first 3 years and then yearly), we considered the eGFR measurement closest to the end of the period for each patient. Mixed models with repeated measurements were applied to measure the change from baseline in eGFR at each time point and to calculate the p-value for the difference between groups (presented near each point). GLP-1 RAs Glucagon-like peptide-1 receptor agonists, eGFR estimated glomerular filtration rate